Sarepta Therapeutics, Inc. (SRPT:NASDAQ) closed at $16.42 on November 10, 2026, down 4.76% on the day. The stock trades 33.5% below its 52-week high of $24.68 and 11.9% above its 52-week low of $14.68. Over the past year, it lost 8.7%. Sarepta Therapeutics, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 10, 2025, SRPT closed higher on 123 days (49%). Its best day was March 25, 2026 (+34.98%) and its worst was February 5, 2026 (-13.68%). The stock moved 10% or more in a single session 4 times. It opened at least 5% above the previous day's high 1 time.
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. The company has a strategic alliance with Nationwide Children's Hospital for the advancement of microdystrophin gene therapy program under the research and option agreement, as well as Galgt2 gene therapy program under the license agreement; Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD under the research collaboration agreement; and Charley's Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies under the research agreement. It also has a license agreement with the University of Western Australia for treatment of DMD by inducing the skipping of certain exons; and collaboration and license agreement with...
Find more stocks like SRPT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.